Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (211-220 of 347) with videos related to

Pageof 35
Sort By:
Japanese Journal of Clinical Oncology|April 10, 2015
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST studyYisheng Huang, Li Zhang, Yuankai Shi, et al.
Personalized Medicine|May 18, 2018
Ventana immunohistochemistry ALK (D5F3) detection of ALK expression in pleural effusion samples of lung adenocarcinomaZheng Wang, Xiaonan Wu, Yuankai Shi, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|May 25, 2016
[Efficacy of Cetuximab in Combination with Chemotherapy in Advanced Non-small Cell Lung Cancer]Sheng Yang, Yan Wang, Xingsheng Hu, et al.
Cancer Research|September 2, 2008
Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancerTong Sun, Yifeng Zhou, Ming Yang, et al.
Leukemia Research|October 8, 2014
The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphomaXiaohong Han, Jianfei Wang, Ningning Zhang, et al.
Cancer Pathogenesis and Therapy|October 7, 2024
Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trialChanggong Zhang, Jianhua Chen, Huijuan Wu, et al.
Asia-Pacific Journal of Clinical Oncology|August 12, 2020
R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphomaFengyi Zhao, Yan Qin, Jianliang Yang, et al.
Journal of Cancer Research and Clinical Oncology|April 24, 2023
MYD88<sup>L265P</sup> and MYD88<sup>other</sup> variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphomaYan Qin, Tian Qiu, Zucheng Xie, et al.
Blood Advances|March 26, 2026
Digital Spatial Profiling Uncovers Transcriptomic Features of Distinct Plasma Cell-like Phenotypes in Diffuse Large B-cell LymphomaZucheng Xie, Yan Qin, Xuemin Xue, et al.
Targeted Oncology|April 3, 2020
Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to IbrutinibShiyu Jiang, Yan Qin, Lin Gui, et al.
Pageof 35

Showing results (211-220 of 347) with videos related to

Sort By:
Pageof 35
Japanese Journal of Clinical Oncology|April 10, 2015
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST studyYisheng Huang, Li Zhang, Yuankai Shi, et al.
Personalized Medicine|May 18, 2018
Ventana immunohistochemistry ALK (D5F3) detection of ALK expression in pleural effusion samples of lung adenocarcinomaZheng Wang, Xiaonan Wu, Yuankai Shi, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|May 25, 2016
[Efficacy of Cetuximab in Combination with Chemotherapy in Advanced Non-small Cell Lung Cancer]Sheng Yang, Yan Wang, Xingsheng Hu, et al.
Cancer Research|September 2, 2008
Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancerTong Sun, Yifeng Zhou, Ming Yang, et al.
Leukemia Research|October 8, 2014
The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphomaXiaohong Han, Jianfei Wang, Ningning Zhang, et al.
Cancer Pathogenesis and Therapy|October 7, 2024
Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trialChanggong Zhang, Jianhua Chen, Huijuan Wu, et al.
Asia-Pacific Journal of Clinical Oncology|August 12, 2020
R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphomaFengyi Zhao, Yan Qin, Jianliang Yang, et al.
Journal of Cancer Research and Clinical Oncology|April 24, 2023
MYD88<sup>L265P</sup> and MYD88<sup>other</sup> variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphomaYan Qin, Tian Qiu, Zucheng Xie, et al.
Blood Advances|March 26, 2026
Digital Spatial Profiling Uncovers Transcriptomic Features of Distinct Plasma Cell-like Phenotypes in Diffuse Large B-cell LymphomaZucheng Xie, Yan Qin, Xuemin Xue, et al.
Targeted Oncology|April 3, 2020
Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to IbrutinibShiyu Jiang, Yan Qin, Lin Gui, et al.
Pageof 35